The University of Oxford, the Clinical Research Unit of Nanoro and EVI have launched two new clinical trials to test a next‑generation multi-stage malaria vaccine designed to target two stages together two in the Plasmodium falciparum lifecycle.

Advancing gender equality in science is not only a matter of fairness, but it also directly improves public health, social policy, and innovation by embedding inclusion into how knowledge is produced and applied.

In recent weeks, health authorities in India’s state of West Bengal have confirmed cases of Nipah virus infection amid ongoing surveillance and containment efforts.

The MVPE-CC consortium contributed key evidence reviewed in a joint session of the WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE) and Malaria Policy Advisory Group (MPAG) held in September 2025 for considerations of malaria vaccination schedules in perennial settings. The conclusions and recommendations of the SAGE and MPAG were published in the latest issue of the Weekly Epidemiological Record (No 49, 5 December 2025). December 2025 WHO has recommended two

A newly released video titled Proving the value of malaria vaccines: how case-control studies can guide immunisation strategies looks at the value of case control studies.

EVI is committed to supporting a development pathway that ensures the highest scientific standards from early optimisation through to field evaluation

This comprehensive analysis brings renewed attention to placental malaria (PM), a condition that continues to threaten millions of pregnant women and newborns globally. Drawing on 50 studies conducted since 2013, the review confirms that placental malaria remains highly prevalent in malaria-endemic regions.

On 24-25 November, EVI team members convened at the Woudschoten Conference Center for a two-day retreat focused on strategic alignment, operational updates, and team cohesion. Situated in the tranquil woods near Zeist, Woudschoten offered an ideal backdrop for reflection, collaboration, and a bit of woodland adventure: including a hands-on session that tested the team’s real-time cooperation and adaptation in a fun, yet unexpected setting.

Since welcoming the first fellow in 2015, EVI has supported early- and mid-career researchers from low- and middle-income countries in developing their skills across the vaccine development spectrum.

Vaccines play a vital, but sometimes underappreciated, role in the fight against AMR.

This year, EVI’s dedication to improving maternal and neonatal health was highlighted, with a focus on the development of a placental malaria vaccine.

A two-day translational vaccinology workshop was hosted by EVI and the MRCG. The event was attended by 20 participants from MRCG and 8 from the University of Sierra Leone (USL), as part of the MMVC project.

EVI’s involvement underscored our commitment to strengthening vaccine research capacity, fostering collaboration across diverse research hubs, and sharing our expertise in trial delivery.

A new feature in the EU Horizon Magazine  highlights the ADVANCE-VAC4PM  project, an EU-funded initiative coordinated by the European Vaccine Initiative (EVI),  which is paving the way for the world’s first vaccine to protect against placental malaria . November 2025 Malaria during pregnancy is a leading cause of maternal and infant illness and death across sub-Saharan Africa, resulting in miscarriage, stillbirth, low birth weight, and life-threatening complications. The ADVA

“Vaccines don’t usually stop transmission, and that’s a big problem” - EVI-led NOSEVAC is is exploring how nasal vaccines could reduce transmission of diseases such as influenza, COVID-19, whooping cough, and pneumonia.

The Partnerships & Access session during the World Vaccine Congress Europe 2025 focused on advancing vaccine development through collaboration, funding, and stakeholder engagement.

As the world marks 80 years since the creation of the United Nations, we reflect on the shared global mission to end poverty in all its forms.

September 2025 The European Vaccine Initiative (EVI) was represented at the IMPRINT Network Conference 2025, held in Johannesburg, South...

Dr. Charles Mulamba, recipient of European Vaccine Initiative PhD fellowship, successfully graduated last week at Nelson Mandela African Institution of Science and Technology, Tanzania.

Working with the Inno4Vac consortium coordinated by European Vaccine Initiative, Naobios will leverage Nuvonis’s Vero Cell Bank to...

This EVI-sponsored clinical trial of the full-length MSP1/GLA-SE vaccine candidate, reflects our commitment to innovation in malaria vaccine development.

New EVI-led project aims to boost malaria control with innovative vaccine technology through international partnership and support by the Global Health Innovative Technology (GHIT) Fund with an investment of approximately JPY 800 million. The core aim of SEmalvac6 is to advance the biomanufacture and preclinical development of the blood-stage malaria vaccine candidate SE36/cVLP.

The SUNSHINE trial has now proceeded to the start of vaccination of participants living in Shigella endemic setting at the Centre for Infectious Disease Research in Zambia (CIDRZ).

A delegation from BioNTech visited the European Vaccine Initiative (EVI) to engage in a dialogue focused on strengthening global capacity building efforts and supporting scientific training for fellows hosted by both organisations.